153 related articles for article (PubMed ID: 23653048)
21. Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.
Yin MB; Li ZR; Cao S; Durrani FA; Azrak RG; Frank C; Rustum YM
Mol Pharmacol; 2004 Jul; 66(1):153-60. PubMed ID: 15213307
[TBL] [Abstract][Full Text] [Related]
22. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
23. Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1.
Hinrichsen I; Ernst BP; Nuber F; Passmann S; Schäfer D; Steinke V; Friedrichs N; Plotz G; Zeuzem S; Brieger A
Mol Cancer; 2014 Jan; 13():11. PubMed ID: 24456667
[TBL] [Abstract][Full Text] [Related]
24. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Ambrosini G; Seelman SL; Qin LX; Schwartz GK
Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
[TBL] [Abstract][Full Text] [Related]
25. Potential role of MLH1 in the induction of p53 and apoptosis by blocking transcription on damaged DNA templates.
Yanamadala S; Ljungman M
Mol Cancer Res; 2003 Aug; 1(10):747-54. PubMed ID: 12939400
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Nitrogen Permease Regulator Like-2 (NPRL2) Enhances Sensitivity to Irinotecan (CPT-11) in Colon Cancer Cells by Activating the DNA Damage Checkpoint Pathway.
Liu S; Liu B
Med Sci Monit; 2018 Mar; 24():1424-1433. PubMed ID: 29519997
[TBL] [Abstract][Full Text] [Related]
27. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
28. Ionizing radiation, inflammation, and their interactions in colon carcinogenesis in Mlh1-deficient mice.
Morioka T; Miyoshi-Imamura T; Blyth BJ; Kaminishi M; Kokubo T; Nishimura M; Kito S; Tokairin Y; Tani S; Murakami-Murofushi K; Yoshimi N; Shimada Y; Kakinuma S
Cancer Sci; 2015 Mar; 106(3):217-26. PubMed ID: 25529563
[TBL] [Abstract][Full Text] [Related]
29. Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.
Stubbert LJ; Smith JM; McKay BC
BMC Cancer; 2010 May; 10():207. PubMed ID: 20470425
[TBL] [Abstract][Full Text] [Related]
30. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
31. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM
Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738
[TBL] [Abstract][Full Text] [Related]
32. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
Alotaibi M; Sharma K; Saleh T; Povirk LF; Hendrickson EA; Gewirtz DA
Radiat Res; 2016 Mar; 185(3):229-45. PubMed ID: 26934368
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
[TBL] [Abstract][Full Text] [Related]
35. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
36. MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea.
McDaid JR; Loughery J; Dunne P; Boyer JC; Downes CS; Farber RA; Walsh CP
Br J Cancer; 2009 Aug; 101(3):441-51. PubMed ID: 19623177
[TBL] [Abstract][Full Text] [Related]
37. Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.
Hinrichsen I; Ackermann A; Düding T; Graband A; Filmann N; Plotz G; Zeuzem S; Brieger A
Mol Carcinog; 2017 Jul; 56(7):1816-1824. PubMed ID: 28224663
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
39. MLH1 function is context dependent in colorectal cancers.
Jackson T; Ahmed MA; Seth R; Jackson D; Ilyas M
J Clin Pathol; 2011 Feb; 64(2):141-5. PubMed ID: 21169277
[TBL] [Abstract][Full Text] [Related]
40. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors.
Takahashi T; Min Z; Uchida I; Arita M; Watanabe Y; Koi M; Hemmi H
Cancer Lett; 2005 Mar; 220(1):85-93. PubMed ID: 15737691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
